Alphathera

Alpha-emitters are potent radio isotopes which can be important in the treatment of cancer. Although there are many developments with 225Ac (actinium), Coretag Holding decided to launch Alphathera AG as a subsidiary focusing on the development of 212Pb (lead) targeted radiotherapy in combination with proven targeting molecules.